Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Metairie, Louisiana 70006


This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Study summary:

Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.


Inclusion Criteria: - Thrombocytopenia with bone marrow findings showing normal or increased numbers of megakaryocytes. - Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy and post splenectomy steroids. - Platelet count of 30,000 or less. - Performance status score of 2 or less. - Adequate organ function: *bilirubin< 2; *AST < 3 times normal; *creatinine < 2. - No prior treatment with anthracycline or chemically related drugs. Exclusion Criteria: - Pregnant or lactating women. - Presence of a malignancy other than basal cell carcinoma of the skin.



Primary Contact:

Principal Investigator
Thomas M Cosgriff, MD
Hematology and Oncology Specialists

Backup Contact:


Location Contact:

Metairie, Louisiana 70006
United States

Mary Ann Ostroske, RN
Phone: 504-894-7115
Email: mostroske1@salco.net

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.